Product Information
HYDROXYZINE PAM 50 MG CAP is a generic product labeled by Chartwell RX LLC, priced at $0.0820 per EA under NDC 62135081712. Its NADAC has been published 122 times since Jun 5, 2024.
FDA first approved this application on Jun 3, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
50 mg/1
Manufacturer
Chartwell RX LLCNDC
62135081712
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
HYDROXYZINE PAMOATEApproval Type
Generic (ANDA)
FDA Application
ANDA201507FDA Approved
6/3/2013
TE Code
AB
On Market Since
6/3/2013
Pharmacological Classes
Price Statistics
The NADAC for HYDROXYZINE PAM 50 MG CAP has been published 122 times since Jun 5, 2024, and over the history we have for it it has risen 17.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0820 per EA |
|---|---|
| All-time high | $0.0851 (Dec 10, 2025) |
| All-time low | $0.0683 (Jul 17, 2024) |
| 52-week high | $0.0851 |
| 52-week low | $0.0796 |
| Median price | $0.0816 |
| Average price | $0.0798 |
| Largest weekly change | -14.7% (Nov 20, 2024) |
| Weeks tracked | 122 |
| Tracking since | Jun 5, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Hydroxyzine pamoate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Chartwell RX LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Hydroxyzine pamoate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antihistamine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of HYDROXYZINE PAM 50 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for HYDROXYZINE PAM 50 MG CAP, manufactured by Chartwell RX LLC, is $0.0820 per EA (NDC 62135081712), effective Sep 30, 2026.
How has the price of HYDROXYZINE PAM 50 MG CAP changed over time?
Over the history we have for it, the NADAC for HYDROXYZINE PAM 50 MG CAP has risen 17.7%. It has been tracked across 122 weekly CMS publications since Jun 5, 2024.
What are the highest and lowest recorded NADAC prices for HYDROXYZINE PAM 50 MG CAP?
Since Jun 5, 2024, the NADAC for HYDROXYZINE PAM 50 MG CAP has ranged from a low of $0.0683 (Jul 17, 2024) to a high of $0.0851 (Dec 10, 2025), with a median of $0.0816 per EA.
Are there cheaper alternatives to HYDROXYZINE PAM 50 MG CAP?
No other NADAC-published product currently shares the active ingredient and strength of HYDROXYZINE PAM 50 MG CAP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures HYDROXYZINE PAM 50 MG CAP?
HYDROXYZINE PAM 50 MG CAP (NDC 62135081712) is labeled by Chartwell RX LLC, and CMS classifies it as a generic product.